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The	Problem	
	
Neoadjuvant	therapy	has	emerged	as	an	
alterna∗ve	treatment	strategy	for	poten∗ally	
resectable	pancrea∗c	cancer.		
	
In	the	tradi∗onal	surgery	ﬁrst	approach,	up	to	
50%	of	pa∗ents	failed	to	receive	adjuvant	
therapy	due	to	early	disease	reoccurrence,	
post-opera∗ve	complica∗ons	or	decline	in	
func∗on	hence	rendering	costly	and	high-risk	
surgery	ul∗mately	fu∗le.		
	
		
Currently	upfront	surgery	and	
adjuvant	therapy	is	
recommended	for	cases	of	
resectable		pancrea∗c	cancer	
	
Neoadjuvant	therapy	is	widely	
supported	for	locally	
advanced	and	borderline	
cases.		
Aim	
	
Cost-eﬀec∗veness	analysis	
comparing	neoadjuvant	v	
surgery	ﬁrst	approach	to	
the	management	of	
poten∗ally	resectable	
pancrea∗c	cancer.		
Challenge	
	
¥  Lack	of	level	1	evidence	
¥  Lack	of	true	like-for-like	comparisons	between	
treatment	strategies	
¥  Heterogeneity	of	treatment	regimes		
	
	
Strategy	For	Change	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Evidence	Synthesis	
	
¥  Meta-analysis	of	pooled	
propor∗ons	
	
Markov	Model	
	
	
	
	
	
	
	
	
Cost	Eﬀec∗veness	Analysis	
	
	
	
	
	
	
	
	
	
¥  Eﬀec∗veness:	quality-adjusted-life-months	
(QALMs)		
¥  1	Markov	cycle	=	1month		
¥  Total	follow-up	∗me	of	60	cycles	or	un∗l	
death.	Discount	for	cost	and	beneﬁt:	3.5	
¥  Model	uncertain∗es	were	tested	through	one	
and	two-way	determinis∗c	and	probabilis∗c	
Monte	Carlo	sensi∗vity	analysis.		
Results	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
¥  Surgery	ﬁrst	pathway:	17.59	QALMs	at	a	cost	eﬀec∗veness	ra∗o	of	£5582.85.	
¥  Neoadjuvant	pathway	gave	15.46	QALMs	at	a	cost	eﬀec∗veness	ra∗o	of	£4311.02.		
¥  This	meant	the	surgery	ﬁrst	had	an	incremental	eﬀec∗veness	of	2.13	QALMs	with	an	
incremental	cost	eﬀec∗veness	ra∗o	of	£14804.81.		
¥  When	willingness-to-pay	was	set	at	£30,000	per	QALY	as	per	NICE	guidelines,	
neoadjuvant	pathway	was	then	most	cost-eﬀec∗ve	pathway	for	treatment	of	
pa∗ents	with	poten∗ally	resectable	pancrea∗c	cancer.				
Take	Home	Message	
	
Cost-eﬀecΓveness	analysis	adds	an	
important	dimension	to	the	debate	
Costs	and	beneﬁts	in	cancer	treatment	are	
mulΓfaceted	and	complex	
	Greater	paΓent	and	carer	input	in	future	
research		
Future	research	focus	on	personalised	
predicΓve	medicine		to	support	shared	
clinical	decision-making	and	beΠer	
streamlining	of	services	to	meet	individual	
paΓent	needs.		
	
